CAR-T Will Transform the Treatment of Malignant Diseases, But Challenges Remain in Selection, Logistics, and Toxicity
Interview:
CAR-T therapy is evolving rapidly, and we have only seen the beginning of this revolution in cancer treatment. Julian Hamfjord, Consultant Clinical Oncologist at the lymphoma section of Oslo University Hospital, shares his insights in this interview.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
